Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Palisade Bio, Inc. PALI NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
34/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.50
-27.2%

Palisade Bio, Inc. (PALI) is a Biotechnology company in the Healthcare sector, currently trading at $2.06. It has a SharesGrow Score of 33/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is PALI = $2 (-27.2% upside).

Valuation: PALI trades at a trailing Price-to-Earnings (P/E) of -6.5 (S&P 500 average ~25).

Net income is $17M (loss), growing at -6.6%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $71,000 against $129M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 28.95 (strong liquidity). Debt-to-assets is 0.1%. Total assets: $134M.

Analyst outlook: 3 / 3 analysts rate PALI as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 64/100 (Pass), Income ?/100 (Fail).

$1.50
▼ 27.18% Downside
Average Price Target
The 12-month price target for Palisade Bio, Inc. is $1.50.

PALI SharesGrow Score Overview

40/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PALI

✗
VALUE Fail
10/100
PALI trades at a trailing Price-to-Earnings (P/E) of -6.5 (S&P 500 average ~25). Forward PEG -0.23 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $2, implying -2.9% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
PALI: -100%/yr revenue is, -6.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet PALI: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 28.95 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
PALI: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 3 / 3 analysts rate PALI as buy (100%). Analyst consensus target is $2 (-2.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.53-2.64
Volume4.04M
Avg Volume (30D)4.41M
Market Cap$341.72M
Beta (1Y)1.47
Share Statistics
EPS (TTM)-0.30
Shares Outstanding$55.67M
IPO Date2007-03-30
Employees8
CEOJ. D. Finley
Financial Highlights & Ratios
Gross Profit$-3K
EBITDA$-18.06M
Net Income$-16.78M
Operating Income$-18.06M
Total Cash$133.39M
Total Debt$71K
Net Debt$-133.31M
Total Assets$134.34M
Price / Earnings (P/E)-6.9
Analyst Forecast
1Y Price Target$1.50
Target High$1.50
Target Low$1.50
Upside-27.2%
Rating ConsensusBuy
Analysts Covering3
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS6963894026

Price Chart

Track all markets on TradingView
PALI
Palisade Bio, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.53 52WK RANGE 2.64

People Also View

IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.94
+4.83%
 NBY
NBY
NovaBay Pharmaceuticals, Inc.
$1.88
-3.59%
 PHIO
PHIO
Phio Pharmaceuticals Corp.
$1.29
+4.03%
 APGN
APGN
Apexigen, Inc.
$0.39
+8.48%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
 ENVB
ENVB
Enveric Biosciences, Inc.
$1.95
-1.02%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message